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Cellular responses to epidermal growth factor (EGF) are dependent on the tyrosine-specific protein kinase
activity of the cell-surface EGF receptor. Previous studies using WB rat liver epithelial cells have detected at
least 10 proteins whose phosphotyrosine (P-Tyr) content is increased by EGF. In this study, we have examined
alternate modes of activating tyrosine phosphorylation. Treatment of WB cells with hormones linked to Ca2+
mobilization and protein kinase C (PKC) activation, including angiotensin II, [Arg8]vasopressin, or epineph-
rine, stimulated rapid (<15-s) and transient increases in the P-Tyr content of several proteins (p120/125,
p75/78, and p66). These proteins, detected by anti-P-Tyr immunoblotting, were similar in molecular weight to
a subset of EGF-sensitive P-Tyr-containing proteins (P-Tyr-proteins). The increased P-Tyr content was
confirmed by [32P]phosphoamino acid analysis of proteins recovered by anti-P-Tyr immunoprecipitation.
Elevating intracellular [Ca21] with the ionophore A23187 or ionomycin or with the tumor promoter
thapsigargin mimicked the effects of hormones on tyrosine phosphorylation, whereas treatment with a
PKC-activating phorbol ester did not. In addition, responses to angiotensin II were not diminished in
PKC-depleted cells. Ca21 mobilization, measured by fura-2 fluorescence, was coincident with the increase in
tyrosine phosphorylation in response to angiotensin II or thapsigargin. Loading cells with the intracellular
Ca2+ chelator bis-(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) inhibited the appearance of
all P-Tyr-proteins in response to angiotensin II, thapsigargin, or ionophores, as well as two EGF-stimulated
P-Tyr-proteins. The majority of EGF-stimulated P-Tyr-proteins were not affected by BAPTA. These studies
indicate that angiotensin II can alter protein-tyrosine phosphorylation in a manner that is secondary to, and
apparently dependent on, Ca2+ mobilization. Thus, ligands such as EGF and angiotensin II, which act through
distinct types of receptors, may activate secondary pathways involving tyrosine phosphorylation. These results
also raise the possibility that certain growth-promoting effects of Ca2+-mobilizing agents such as angiotensin
H may be mediated via tyrosine phosphorylation.
Reversible phosphorylation of proteins is a major mecha-
nism by which metabolic processes are regulated. Phosphor-
ylation on serine and threonine residues, which together
account for >99% of total cellular protein phosphate, are
recognized as key elements in the regulation of such diverse
pathways as glycogen metabolism, protein biosynthesis, and
cell surface receptor signaling (19). Phosphorylation on
tyrosine residues, which accounts for <0.5% of protein-
bound phosphate (12), has been linked broadly with the
control of cell proliferation. Receptors for several growth
factors, including epidermal growth factor (EGF) and plate-
let-derived growth factor, contain ligand-activated, tyrosine-
specific protein kinase domains essential for biological ac-
tivity (76, 78). Similarly, the protein products of several
oncogenes (e.g., src and ab) exhibit tyrosine kinase activi-
ties essential for oncogenic transformation (36, 41).
The identities of relevant substrates for tyrosine kinases
remain largely obscure because of the technical challenge of
monitoring transient tyrosine phosphorylation events against
high backgrounds of serine/threonine phosphorylation and
because of the complex and temporally protracted nature of
mitogenesis. Nevertheless, several potential substrates for
tyrosine kinases in intact cells have been identified, using
combinations of 32p labeling, electrophoresis, phosphoami-
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no acid analysis, and immunoprecipitation and immunoblot-
ting with antiphosphotyrosine (anti-P-Tyr) antibodies. One
group of substrates are structural proteins, including vincu-
lin, the fibronectin receptor, ezrin, and calpactins I and II
(reviewed in reference 9). Several proteins likely to propa-
gate acute growth factor receptor signals also have been
identified as tyrosine kinase substrates: phosphatidylinositol
kinase, phosphoinositide (Ptdlns)-specific phospholipase
C-y(PLC-y), the ras GTPase-activating protein, and the
serine/threonine kinases Raf-1 and microtubule-associated
protein 2 (MAP-2) kinase (56, 76).
Our laboratory has studied the regulation of EGF signal-
ling in the nontransformed rat liver epithelial cell line WB
(71), which expresses EGF receptors at levels (2 x 105 to 3
X 105 per cell) comparable to those in hepatocytes. Expo-
sure ofWB cells to EGF provokes a cascade of events: EGF
receptor tyrosine autophosphorylation and phosphorylation
of other cellular proteins (-5 s); production of Ca2+-mobi-
lizing inositol phosphates, activation of protein kinase C
(PKC), and receptor internalization (1 to 2 min) and, after a
period of hours, protein and DNA synthesis (38, 49, 71).
These cells also express receptors for several hormones
(e.g., angiotensin II, [Arg8]vasopressin, and epinephrine)
whose actions are believed to be mediated by non-tyrosine
kinase-containing receptors coupled principally to Ca2+ mo-
bilization and PKC activation. These hormones increase
EGF receptor mRNA and protein levels by a mechanism
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partly independent of PKC (18). Activation of PKC by
phorbol esters can inhibit EGF-stimulated Ptdlns hydrolysis
(38), EGF receptor kinase activity, and tyrosine phosphor-
ylation of PLC-y in WB cells (W. R. Huckle, J. R. Hepler,
S. G. Rhee, T. K. Harden, and H. S. Earp, Endocrinology,
in press); phorbol ester treatment likewise can uncouple
angiotensin II receptors from ligand-stimulated PtdIns hy-
drolysis (38). While investigating possible heterologous de-
sensitization of the EGF receptor kinase by other PKC-
activating agonists in WB cells, we noted that angiotensin II
itself stimulated increases in the tyrosine phosphorylation of
several proteins. In this work, we report this effect and
present evidence that it is dependent on increases in cyto-
solic Ca2" levels. These findings indicate that hormone
receptors not thought to possess intrinsic tyrosine kinase
activity may nonetheless signal through tyrosine phosphor-
ylation and suggest a mechanism by which their ligands elicit
effects similar to those of recognized growth factors.
MATERIALS AND METHODS
Materials. EGF was purified from mouse salivary glands
as described previously (58). Human sequence angiotensin II
(Asp Arg Val Tyr Ile His Pro Phe), [Arg8]vasopressin,
(-)-epinephrine (Sigma), and EGF were prepared as 100-
fold-concentrated solutions in 10 mM NaPi-150 mM NaCl
(pH 7.4) containing 0.1% bovine serum albumin. Phorbol
12-myristate 13-acetate (PMA; Sigma), thapsigargin (LC
Services), bis-(O-aminophenoxy)ethane-N,N,N',N'-tetra-
acetic acid, tetraacetoxymethyl ester (BAPTA-AM; GIBCO-
BRL), ionomycin, A23187 (Calbiochem), and fura-2, tetra-
acetoxymethyl ester (fura-2-AM; Molecular Probes) were
prepared as stock solutions in dimethyl sulfoxide; final
vehicle concentration was <0.1% (vol/vol). Polyclonal anti-
P-Tyr antibodies were prepared as described previously (49)
except that affinity purification was performed by chroma-
tography on immobilized phosphotyramine.
Cell cultures. WB cells were maintained at 37°C in Richter
improved minimal essential medium containing 10% fetal
bovine serum and 0.1 ,uM insulin in a humidified 5% CO2
atmosphere as described previously (38). Seven to ten days
before each experiment, cells of passages 19 to 26 were
seeded onto plastic culture dishes (Costar) or glass cover
slips (Fisher). Except where indicated, cells were used for
experiments 1 to 2 days after reaching confluence. Before
addition of EGF, angiotensin II, or other agents, cells were
washed once with Eagle minimal essential medium contain-
ing 20 mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic
acid (EMEM-HEPES, pH 7.3) and were allowed to equili-
brate in this medium for 15 min at 37°C.
Anti-P-Tyr immunoblotting. Cell treatments and anti-P-
Tyr immunoblotting were performed essentially as described
previously (49), using WB cells grown in 35-mm-diameter
culture dishes. Briefly, treatment incubations were termi-
nated by rapid aspiration of the medium and addition of 250
iil ice-cold RIPA buffer (49). Cell extracts were scraped from
culture dishes and solubilized by addition of 125 ,ul of
threefold-concentrated sodium dodecyl sulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE) sample buffer and
heating to 100°C for 3 min. Proteins were separated by
electrophoresis on 7 or 10% polyacrylamide gels and trans-
ferred to nitrocellulose membranes. Blots were probed by
sequential incubation with affinity-purified anti-P-Tyr anti-
bodies and 125I-protein A (2 to 10 ,uCi/,ug; Dupont-New
England Nuclear), followed by autoradiography. Molecular
weights of P-Tyr-containing proteins (P-Tyr-proteins) were
estimated by using prestained standards calibrated by com-
parison with the migration of nonprestained standards (Sig-
ma). Relative intensities of autoradiographic bands were
estimated by scanning densitometry (LKB Ultroscan XL).
The appearance of all autoradiographic bands could be
completely blocked by addition of 1 mM phenylphosphate or
P-Tyr during the antibody incubation. In some experiments,
blots were probed with monoclonal anti-P-Tyr antibody
PY20 (29) (1 ,ug/ml; ICN ImmunoBiologicals), followed by
rabbit anti-mouse immunoglobulin G (1 ,ug/ml; Jackson
ImmunoResearch) and 1251I-protein A.
Phosphoamino acid analysis. Confluent WB cell cultures in
60-mm-diameter dishes were prelabeled by incubation (2 h,
37°C) with 1 mCi of H332Po4 (>8,500 Ci/mmol; Dupont-New
England Nuclear) in 3 ml of phosphate-free EMEM-HEPES
supplemented with 0.5% fetal bovine serum. After treatment
with EGF or other agents, the medium was aspirated, and
cells were scraped from the dishes in 0.3 ml of ice-cold lysis
buffer (20 mM HEPES [pH 7.3], 50 mM NaF, 10% [vol/vol]
glycerol, 1% [wt/vol] Triton X-100, 1 mM sodium o-vana-
date, 10 ,ug of phenylmethylsulfonyl fluoride per ml). Ly-
sates were tumbled for 30 min at 4°C and then centrifuged at
12,000 x g for 15 min at 4°C. Supernatants were transferred
to conical 15-ml polypropylene tubes, brought to 1% SDS
and 100 mM 2-mercaptoethanol, and heated to 100°C for 5
min. Samples were chilled on ice and diluted to 3 ml with
lysis buffer. P-Tyr-proteins were immunoprecipitated by
incubation (2 h, 4°C) with 1 ,ug of monoclonal anti-P-Tyr
antibody PY20, 5 ,ug of rabbit anti-mouse immunoglobulin
G, and 10 ,ul of Pansorbin (Calbiochem). Immunoprecipi-
tates were recovered by centrifugation and washed by
sequential suspension and centrifugation in lysis buffer plus
(i) 0.1% SDS, (ii) 0.5 M NaCl, and (iii) 0.1% SDS. Immuno-
precipitates then were solubilized for SDS-PAGE on 7%
polyacrylamide gels. Phosphoproteins were transferred to
Immobilon membranes and were located by autoradiogra-
phy. Bands of interest were excised from the Immobilon blot
and subjected to acid hydrolysis (43), two-dimensional elec-
trophoresis (12), and autoradiography.
Measurement of intracellular Ca2". Calcium monitoring
was performed essentially as described previously (77). WB
cells were grown on 22-by-22-mm glass cover slips to ap-
proximately 80% confluence. Cells were chilled to 4°C for 5
min in EMEM-HEPES and then loaded with the fluorescent
Ca2+ indicator fura-2 (34) by incubation with 5 ,uM fura-
2-AM for 15 min at 37°C. After three washes with EMEM-
HEPES, the cover slips were mounted on the stage of a
digital video fluorescence microscope. Fluorescence (340-
and 380-nm excitation; >440-nm emission) was monitored at
15- to 30-s intervals before and after treatment of cells with
angiotensin II or thapsigargin. Free [Ca2+] was calculated by
the ratio method, with correction for background fluores-
cence (80).
RESULTS
Angiotensin II and [Arg8]vasopressin increase protein-ty-
rosine phosphorylation in WB cells. As reported previously
(49), EGF stimulated rapid (c5-s) increases in the tyrosine
phosphorylation of several proteins, the most prominent
being the 170-kDa EGF receptor (Fig. 1). Treatment with
angiotensin II provoked increases in the tyrosine phosphor-
ylation of several species similar in molecular weight to
those affected by EGF: p120/125, p75/78, and p66 (Fig. 1).
On shorter autoradiographic exposures, the species of 120/
125 and 75/78 kDa could be resolved as doublet bands (Fig.
VOL. 10, 1990
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FIG. 1. EGF- and angiotensin II-stimulated tyrosine phosphorylation. WB cells were treated with EGF (300 ng/ml) or angiotensin II (1
p.M) for the times indicated (in seconds), and tyrosine phosphorylation was assessed by anti-P-Tyr immunoblotting after SDS-PAGE on 7%
polyacrylamide gels as described in Materials and Methods. Autoradiographs shown (representative of three separate experiments) were
exposed for 2 (A) or 6 (B) days at -70°C.
1A). Angiotensin TI-stimulated increases in less prominent
species, P-Tyr-p57, -p93, and -p115, were evident upon
longer autoradiographic exposures (Fig. 1B). Similar pat-
terns of tyrosine phosphorylation were observed when blots
were probed with either purified polyclonal anti-P-Tyr anti-
bodies or monoclonal antibody PY20 (not shown). The
response to angiotensin II was both rapid and transient, with
maximal increases in P-Tyr-p66, -p75/78, and -p120/125
occurring between 30 and 60 s of treatment. Phosphorylation
of the p75/78 doublet persisted above basal levels for >5
min, although an increase in the intensity of the upper band,
and concomitant decrease in the intensity of the lower band,
occurred over 5 min of treatment. In contrast, increased
P-Tyr-p66 was no longer detected after 2 min of angiotensin
II treatment. Elevated tyrosine phosphorylation was detect-
able at angiotensin II concentrations as low as 1 nM; the
angiotensin II effects could be blocked by the receptor
antagonist [Sar1, Val5, Ala8]angiotensin.
Although both EGF and angiotensin II affected the ty-
rosine phosphorylation of several proteins similar in molec-
ular weight (p57, p66, p75/78, p93, and p120/125), other
species (pl70/EGF receptor, p59, and p40) were unique to
EGF-treated cells. Similarly, PLC-y is phosphorylated on
tyrosine in response to EGF but not angiotensin II (38a).
Initial attempts to separate EGF- and angiotensin Il-depen-
dent substrates into cytosolic and membrane fractions by
conventional procedures were complicated by rapid losses
of P-Tyr, even in the presence of phosphatase inhibitors.
Homogenization and fractionation at pH 9.5, however, in-
hibited loss of P-Tyr from EGF- and angiotensin II-sensitive
proteins and revealed that all angiotensin II-stimulated
bands, as well as the EGF-sensitive bands of similar molec-
ular weight (p120, p75, and p66), partitioned into the super-
natant fraction (105,000 x g; W. R. Huckle, C. A. Prokop,
and H. S. Earp, unpublished results).
Treatment of WB cells with another peptide hormone,
[Arg8]vasopressin (Fig. 2), or with the adrenergic receptor
agonist epinephrine (not shown) produced increases in ty-
rosine phosphorylation similar to that seen in response to
angiotensin II. This effect of epinephrine was not obtained
with the 3-adrenergic receptor-selective agonist isoprotere-
nol or with the membrane-permeant compound dibutyryl
cyclic AMP (Huckle et al., unpublished results).
Increases in cytosolic calcium mimic the effects of angioten-
sin II on tyrosine phosphorylation. Activation of the angio-
tensin receptor is recognized to produce PKC-activating
diacylglycerols and Ca2"-mobilizing inositol phosphates. To
test the role of cytosolic Ca2" in the angiotensin Il-stimu-
lated increase in tyrosine phosphorylation, WB cells were
treated with other agents that increase intracellular Ca2"








FIG. 2. [Arg8]vasopressin-stimulated increase in tyrosine phos-
phorylation. WB cells were treated with 1 p.M [Arg8]vasopressin
(AVP) for the times indicated; tyrosine phosphorylation then was
assessed by immunoblotting as described in Materials and Methods.
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FIG. 3. Effects of Ca2+-elevating agents on WB cell tyrosine
phosphorylation. WB cells were treated with various Ca2+-mobiliz-
ing agents for periods yielding maximal tyrosine phosphorylation
response: angiotensin II (A II; 1 ,uM, 45 s), thapsigargin (THAPS; 2
pLM, 5 min), ionomycin (IONO; 10 ,uM, 1 min), and A23187 (10 ,uM,
S min) in the absence of o-vanadate or ionomycin (10 ,uM, 2.5 min)
or A23187 (10 ,uM, 5 min) in the presence of 200 ,uM o-vanadate
(15-min preincubation). Results shown are representative of three
separate experiments.
is postulated to allow the release of Ca2+ from inositol
trisphosphate-sensitive stores (65), produced a pattern of
protein-tyrosine phosphorylation strongly resembling that
seen in response to angiotensin II, as did the calcium
ionophores A23187 and ionomycin. The phosphatase inhib-
itor o-vanadate alone (200 ,uM, 15 min) produced small
increases in tyrosine phosphorylation. o-Vanadate enhanced
the response to either ionophore, but its effect on A23187
action was more pronounced, allowing the detection of
several species in the 50- to 90-kDa range not seen in
angiotensin II-treated cells (Fig. 3).
To corroborate the results obtained by anti-P-Tyr immu-
noblotting, 32Pi-labeled WB cells were treated with EGF,
angiotensin II, or A23187 plus o-vanadate. [32P]Tyr-contain-
ing proteins were recovered by anti-P-Tyr immunoprecipita-
tion, separated by SDS-PAGE, and transferred to Immo-
bilon membranes. Autoradiography revealed patterns of
increased phosphorylation similar to those observed by
using anti-P-Tyr immunoblotting. These experiments (Fig. 4)
confirmed that proteins in the molecular weight ranges
detected by immunoblotting (Fig. 1 to 3) did contain elevated
P-Tyr content as a consequence of treatment with angioten-
sin II or A23187.
To test the potential involvement of PKC in angiotensin
II-dependent tyrosine phosphorylation, WB cells were
treated with PMA, an exogenous activator of PKC. Acute
PMA treatment (300 nM, 0.25 to 10 min) produced small
increases in P-Tyr-p120/125 and P-Tyr-p75/78 in two of four
replicate experiments and no effects in the remaining exper-
iments (not shown).
Angiotensin H-stimulated increases in tyrosine phosphory-
lation are coupled to calcium mobilization. To examine the
temporal relationship between Ca2+ mobilization and ty-
rosine phosphorylation, cytosolic Ca2+ levels were moni-
tored in cells loaded with the fluorescent indicator fura-2.
The Ca2+ responses to angiotensin II or thapsigargin were
FIG. 4. Phosphoamino acid analysis of 32P-p75n8. WB cells
were prelabeled with 32P for 2 h before treatment with vehicle (A),
300 ng of EGF per ml (B), 1 ,uM angiotensin 11 (C), or 10 ,uM A23187
plus 200 p.M o-vanadate (D). 32P-proteins were recovered by mono-
clonal anti-P-Tyr immunoprecipitation and subjected to SDS-PAGE
and phosphoamino acid analysis as described in Materials and
Methods. Results (representative of three similar experiments) show
two-dimensional electrophoretic separations of phosphoamino acids
derived from the p75/78 species. In the same experiment, the
p120/125 region from angiotensin II- and A23187-treated cells like-
wise showed increased [32P]Tyr content. The [32P]Tyr spots from
control, EGF-, angiotensin II-, and A23187-treated samples shown
contained 17, 25, 57, and 99 cpm above blank, respectively, deter-
mined by liquid scintillation counting.
coincident with the measurable changes in tyrosine phos-
phorylation (Fig. 5). Angiotensin TI stimulated more rapid
(c5-s) increases in [Ca2"], accompanied by transient in-
creases in P-Tyr-protein levels. The Ca2+ increase in re-
sponse to thapsigargin was maximal after 2 to 3 min and
persisted, along with elevated P-Tyr-proteins, for 25 min.
Thapsigargin stimulates a similarly persistent elevation of
[Ca2+] in hepatocytes (67).
If the increases in tyrosine phosphorylation in response to
angiotensin IT, ionophores, or thapsigargin are secondary to
Ca2+ mobilization, blockade of the Ca2+ increase provoked
by these agents should inhibit their capacity to increase
tyrosine phosphorylation. Treatment of WB cells with an-
giotensin II in the presence of 5 mM EGTA had minimal
effects on the response to angiotensin II (not shown), con-
sistent with the preferred utilization of Ca2+ from intracel-
lular rather than extracellular sources. To block increases in
cytosolic Ca2+ irrespective of its origin, WB cells were
incubated with the membrane-permeant compound BAPTA-
AM, which is hydrolyzed to the active chelator BAPTA
upon entry into cells (72, 73). The concentrations of
BAPTA-AM used were sufficient to inhibit EGF- or angio-
tensin II-induced increases in intracellular [Ca2+] in hepato-
cytes, as measured by digital video fluorescence microscopy
(B. Herman, unpublished data). BAPTA inhibited the in-
creases in all angiotensin II- and thapsigargin-stimulated
P-Tyr-proteins (p66, p75, and p125; Fig. 6); on longer
exposure of autoradiographs from 7% polyacrylamide gels,
blockade of the minor angiotensin II-sensitive species,
P-Tyr-p93 and -p57, also was noted in BAPTA-loaded cells
(not shown). In contrast, BAPTA loading did not inhibit
EGF receptor autophosphorylation (p170), the increases in
VOL. 10, 1990
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FIG. 5. Time courses of angiotensin II- or thapsigargin-stimulated tyrosine phosphorylation and Ca2" mobilization. (A and B) WB cells
in 35-mm-diameter culture dishes were treated with 1 FM angiotensin 11 (A) or 2 ,uM thapsigargin (B) for the times indicated, and tyrosine
phosphorylation was assessed by immunoblotting. Relative intensities of autoradiographic bands in the p75/78 and p120/125 regions were
estimated by scanning densitometry. Data shown (representative of three experiments) are expressed as densitometric peak area (arbitrary
units). (C and D) WB cells grown on 22-by-22-mm cover slips were loaded with fura-2 and monitored for free intracellular [Ca2+] by digital
video fluorescence microscopy as described in Materials and Methods. Each time point is the mean free [Ca2'I across a microscopic field
containing five to six cells selected at random. Results are expressed as the mean + standard error (of three separate experiments) of percent
maximal change in intracellular [Ca2+] ([Ca2+]i) observed in response to 1 ,uM angiotensin 11 (C) or 2 ,uM thapsigargin (D). Preaddition and
peak intracellular [Ca2+] values for angiotensin II-treated cells were 275 + 36 and 1,002 ± 65 nM, respectively; corresponding values for
thapsigargin-treated cells were 320 + 35 and 926 + 185 nM, respectively.
P-Tyr-p115, -p75, and -p59 seen in response to EGF, or the
increases in P-Tyr-plOO and -p40 noted in longer exposures
(not shown). However, BAPTA was noted to inhibit the
EGF-stimulated increases in P-Tyr-p120 and -p66 (Fig. 6).
These results were obtained reproducibly in four separate
experiments. The persistence of EGF receptor phosphory-
lation in the presence of BAPTA is consistent with the
reported insensitivity of the EGF receptor kinase to Ca2+
CONTROL EGF All THAPS





FIG. 6. Effects of BAPTA on tyrosine phosphorylation in WB
cells. WB cells were loaded with BAPTA by preincubation with the
indicated- concentrations of BAPTA-AM for 15 min at 37°C. Cells
were treated with EGF (300 ng/ml, 1 min), angiotensin II (AII; 1 F.M,
45 s), or thapsigargin (THAPS; 2 ,uM, S min), conditions that elicit
maximal tyrosine phosphorylation responses. Immunoblotting was
performed after electrophoresis on 10% polyacrylamide gels, on
which the diffuse angiotensin II-sensitive species of p120/125 and
p75/78 kDa migrated as single bands. Results shown are repre-
sentative of four separate experiments.
(21) and serves as a control for nonspecific or toxic effects of
BAPTA on WB cells. Additional experiments using BAPTA-
loaded cells confirmed that the marked potentiation of
A23187 action by o-vanadate was indeed Ca2+ dependent
(not shown).
As an additional test of the involvement of PKC (a major
intracellular target of mobilized Ca2+) in angiotensin II-
stimulated tyrosine phosphorylation, WB cells were treated
with a high concentration of PMA for 18 h before challenge
with angiotensin II. This pretreatment protocol reduces WB
cell PKC activity to c4% of control levels (38) and elimi-
nates the ability of phorbol esters to inhibit EGF- or angio-
tensin II-stimulated Ptdlns hydrolysis (38) and EGF-stimu-
lated tyrosine phosphorylation of PLC-y (Huckle et al., in
press). In PKC-depleted cells, there was no reduction in the
ability of angiotensin II to increase tyrosine phosphorylation
compared with results for control cells (Fig. 7). In fact, PKC
depletion prolonged the angiotensin II-stimulated elevation
of tyrosine phosphorylation, although increases in magni-
tude were not apparent.
DISCUSSION
The peptide hormone angiotensin II exerts effects on a
variety of tissues, including vascular smooth muscle (vaso-
constriction), the adrenal gland (synthesis and release of
aldosterone and catecholamines), and the liver (glycogenoly-
sis). Activation of angiotensin II receptors typically is asso-
ciated with the generation of Ca2"-mobilizing inositol phos-
phates and PKC-activating diacylglycerols from Ptdlns
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FIG. 7. Effect of PKC depletion on angiotensin II-stimulated
tyrosine phosphorylation. WB cell cultures were treated with 0.1%
dimethyl sulfoxide (A) or 10 ,uM PMA (B) for 18 h before addition of
angiotensin II (All) for the times indicated (", seconds; ', minutes).
Tyrosine phosphorylation then was assessed by anti-P-Tyr immu-
noblotting. Results shown are representative of three separate
experiments.
(reviewed in reference 33). Cellular responses to these
intracellular messengers are thought to be mediated in part
by the targets of PKC and Ca2+/calmodulin-dependent pro-
tein kinases (19). The results of this study on WB cells
suggest that angiotensin II, as well as [Arg8]vasopressin and
epinephrine, also may influence cell function through ty-
rosine phosphorylation. These agents increased the tyrosine
phosphorylation of several proteins, as detected by immu-
noblotting with either affinity-purified polyclonal or mono-
clonal anti-P-Tyr antibodies and confirmed by [32P]phos-
phoamino acid analysis.
Previous studies in WB cells (49) revealed two classes of
proteins whose tyrosine phosphorylation is increased by
EGF: (i) those phosphorylated within 5 to 15 s of EGF
addition (EGF receptor, p115, plO0, p75, p66, p57, and p52)
and (ii) those not detected until 45 to 90 s after EGF addition
(p120, p78, and p38). The first group of proteins also was
phosphorylated, albeit with slower kinetics, when EGF was
added to cells at 4°C (a condition that blocks EGF-stimulated
PtdIns hydrolysis and receptor endocytosis), whereas the
latter group was not detected at 4°C. We postulated that the
temperature-sensitive phosphorylations reflected a require-
ment for dynamic intracellular events, such as EGF receptor
internalization or phosphorylation by another tyrosine ki-
nase activated secondarily by EGF. Indeed, these results
indicate that WB cells contain an angiotensin II-activated
pathway that can increase protein-tyrosine phosphorylation
in a manner apparently independent of the EGF receptor
kinase. Molecular weight profiles and preliminary subcellu-
lar fractionation studies suggest that angiotensin II and EGF
may increase the tyrosine phosphorylation of overlapping
sets of proteins, but more definitive evidence that EGF and
angiotensin II act on identical proteins is needed.
The receptor for angiotensin II is not well characterized
biochemically, although Jackson et al. have reported that the
mas oncogene may encode an angiotensin receptor capable
of coupling to Ca2+ mobilization (42). The predicted amino
acid sequence of neither the mas product nor the al-
adrenergic receptor cDNA (13) indicates the presence of a
tyrosine kinase domain. Instead, available evidence suggests
that receptors of this type activate Ptdlns hydrolysis through
a receptor-associated GTP-binding protein (20, 33, 38a).
Consistent with this proposed mechanism, increases in ty-
rosine phosphorylation stimulated by angiotensin II, [Arg8]
vasopressin, or epinephrine were mimicked by NaF (Huckle
et al., unpublished results), a G-protein activator which
stimulates inositol trisphosphate production in WB cells
(38). Furthermore, similar patterns of tyrosine phosphoryla-
tion also were provoked by the calcium-mobilizing agent
thapsigargin and the Ca2+ ionophores A23187 and ionomy-
cin. All angiotensin II-stimulated increases in P-Tyr-proteins
were blocked by loading cells with the Ca2+ chelator
BAPITA but not by depleting cellular PKC activity. The
effects of angiotensin II on tyrosine phosphorylation thus
appear to be secondary to, and dependent on, Ca2+ mobili-
zation but not PKC activation. The inhibition of EGF-
stimulated tyrosine phosphorylation of p120 and p66 by
BAPTA suggests that these events likewise may be Ca2+
dependent. The failure of BAPTA to inhibit EGF-stimulated
increases in P-Tyr-p75 suggests that this protein is not
identical to the p75 affected by angiotensin II or that distinct
kinases or phosphorylation sites are utilized in response to
EGF and angiotensin II.
Recently, several agents not usually associated with ty-
rosine kinase activity have been found to increase levels of
tyrosine phosphorylation. These include thrombin (22, 30,
46), collagen (50), and vasopressin (32) in platelets, fMet-
LeuPhe in neutrophils (39), muscarinic agonists in hippo-
campal slices (64), and phytohemagglutinin in Jurkat T cells
(69). Disparate findings have been reported regarding the
signaling pathways involved in this atypical tyrosine phos-
phorylation. Several studies using phorbol esters (22, 23, 64)
have indicated a possible role for PKC in tyrosine phosphor-
ylation. In permeabilized neutrophils, GTP-yS-stimulated
increase in P-Tyr-protein levels was not mimicked by exog-
enous diacylglycerols (51), but the role of Ca2+ was not
examined. Other investigators have reported that immuno-
globulin E-stimulated tyrosine phosphorylation in RBL-2H3
basophils proceeds in a Ca2+-independent manner (3). In
contrast, our studies in WB cells establish a link between
hormone-induced Ca2+ mobilization and increased levels of
tyrosine phosphorylation.
While the mechanism by which Ca2+ increases tyrosine
phosphorylation in WB cells has not been determined, the
most straightforward possibility is direct activation of a
tyrosine kinase by Ca2+ or by a Ca2+-binding regulatory
protein. This mechanism would be analogous to regulation of
serine/threonine protein kinases by Ca2+/calmodulin (19). A
related possibility is that Ca2+-dependent enzymes activate
a tyrosine kinase, perhaps by phosphorylation (54) or prote-
olysis. Alternatively, Ca2+ might modulate tyrosine phos-
phorylation by promoting substrate interaction with a ty-
rosine kinase. Precedent for such a model exists in that
lipocortin I (p35; calpactin II) requires Ca2+ in order to bind
to phospholipid membranes and to serve as a substrate for
the EGF receptor tyrosine kinase (17, 21). Similarly, phos-
phorylation of calpactin I (p36; lipocortin II) by the pp6Oc-src
tyrosine kinase is markedly enhanced in the presence of
Ca2' and phospholipid (14, 28).
A third possible mechanism by which Ca2+ might modu-
late tyrosine phosphorylation is inhibition of tyrosine phos-
phatase activity. Recent studies of protein-tyrosine phos-
phatases have demonstrated that these enzymes are greater
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in number and likely are subject to closer regulation than
once was appreciated (40, 70). In our studies, treatment with
o-vanadate alone was accompanied by detectable increases
in the tyrosine phosphorylation of p75/78 and p120/125 (Fig.
3). Thus, p75/78 and p120/125 may continually undergo
phosphorylation and dephosphorylation such that phos-
phatase inhibition alone might permit some accumulation of
their phosphorylated forms. However, angiotensin II, thap-
sigargin, and Ca2+ ionophores clearly have effects on ty-
rosine phosphorylation greater in magnitude than those
induced by o-vanadate alone, and the response to angioten-
sin II or ionophores plus o-vanadate is (at least) additive.
Moreover, the more rapid dephosphorylation of P-Tyr-p66
relative to other angiotensin 1I-sensitive substrates, even in
the presence of o-vanadate (not shown), suggests that inhi-
bition of a single phosphatase cannot account wholly for the
effects of angiotensin II on tyrosine phosphorylation.
o-Vanadate has been reported to have other cellular
effects, including activation of the insulin receptor kinase
(66), a G-protein coupled to PLC (53), and Ca2+ influx (48),
which could partially mimic the effects of angiotensin II. The
potentially pleiotropic effects of o-vanadate may contribute
to the marked synergism between A23187 and o-vanadate
(Fig. 3). Alternatively, the synergism may arise from en-
hanced phosphatase inhibition by supraphysiological intra-
cellular [Ca2+] induced by A23187 or from undetermined
actions of o-vanadate metabolites (44). Regardless of its
molecular mechanism, the marked interaction between
A23187 and o-vanadate indicates that WB cells contain high
levels of latent tyrosine-phosphorylating activity.
Although tyrosine phosphorylation has been studied prin-
cipally in the context of cell proliferation, evidence from
several systems suggests that this protein modification also
may regulate acute metabolic responses to stimuli. A leading
example is the insulin receptor tyrosine kinase (75), which
appears to be essential for insulin-stimulated responses such
as glucose uptake and glycogen synthesis (11). In other
systems, tyrosine phosphorylation has been implicated in
secretion from adrenal chromaffin cells (52), platelets (47),
and basophils (3) and in superoxide production in neutro-
phils (31). The very presence of tyrosine kinases and phos-
phatases in cells which are characteristically nonprolifera-
tive (e.g., neutrophils; 5) or terminally differentiated (e.g.,
neural retina; 62) implies that tyrosine phosphorylation may
participate in a broad spectrum of cellular activities.
Alternatively, angiotensin TI-stimulated tyrosine phos-
phorylation, in addition to serine/threonine phosphorylation,
may be involved in longer-term anabolic responses. Angio-
tensin II increases levels of mRNAs for the EGF receptor in
WB cells (18), angiotensinogen in hepatocytes (2, 45), and
catecholamine-synthesizing enzymes in adrenal meduilary
cells (63). Both angiotensin II (26) and [Arg8]vasopressin (25)
stimulate hypertrophy of vascular smooth muscle cells.
Angiotensin II activates ribosomal S6 kinase (60) and protein
synthesis in smooth muscle cells in a Ca2+-dependent fash-
ion (4). These last findings are especially notable in light of
the recent report that MAP-2 kinase requires phosphoryla-
tion on both tyrosine and threonine residues in order to
activate S6 kinase (1). Thus, MAP-2 kinase (pp42), which
can be phosphorylated on tyrosine in response to EGF,
platelet-derived growth factor, phorbol esters, or thrombin
(56), becomes another candidate for angiotensin IT-stimu-
lated tyrosine phosphorylation. Although we have not de-
tected a P-Tyr-p42 in lysates of angiotensin II-treated WB
cells, this protein, like P-Tyr-PLCy (Huckle et al., in press),
might escape detection without enrichment from lysates.
Finally, tyrosine phosphorylation in response to angioten-
sin II may indicate that this agent shares aspects of mitotic
regulation with recognized tyrosine kinase-linked growth
factors. While the coupling between Ca2" mobilization and
mitogenesis in response to EGF remains enigmatic (6, 8, 10,
16, 74), numerous studies have implicated angiotensin II and
other Ca2+/PKC-linked hormones as regulators of cell pro-
liferation under defined conditions. Angiotensin II, vaso-
pressin, and ac-adrenergic agonists variously stimulate DNA
synthesis in adrenal cortex (27, 55), mouse 3T3 fibroblasts
(57, 59, 61), vascular smooth muscle cells (7), and hepato-
cytes (15). Accordingly, peptide hormones and catechol-
amines have been implicated as regulators of development
(37, 79), angiogenesis (24), and liver regeneration (15). Our
observation that Ca2+-mobilizing agents increase tyrosine
phosphorylation indicates another potential mechanism for
their growth-promoting effects. These results also provide a
new context in which to evaluate both the transforming
activity of the mas oncogene (42) and tumor promotion by
thapsigargin (35), which has been postulated to involve
chronic elevation of intracellular [Ca2+] (68).
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